Figure 1.
Figure 1. A cell-based model of coagulation (see text for further explanation). Adapted from Jurlander B. Seminars in Thrombosis and Haemostasis. 27:373,2001. This model also is amenable to a tissue factor independent mechanism of thrombin generation in the absence of tissue factor and FVIII or FIX, such as would be the condition in severe congenital hemophilia A or B with alloantibody inhibitors or in acquired hemophilia with autoantibody inhibitors. In these situations According to the findings of Monroe et al.13 suprapharmacologic doses of rFVIIa can bind non-specifically to the activated platelet without the requirement of TF and subsequently can activate factor X to Xa in the absence of factor VIII or IX. In contrast, the Mann model14 suggests that suprapharmacologic doses of rFVIIa activates coagulation by overcoming an intrinsic inhibition of zymogen FVII in the absence of TF.

A cell-based model of coagulation (see text for further explanation). Adapted from Jurlander B. Seminars in Thrombosis and Haemostasis. 27:373,2001. This model also is amenable to a tissue factor independent mechanism of thrombin generation in the absence of tissue factor and FVIII or FIX, such as would be the condition in severe congenital hemophilia A or B with alloantibody inhibitors or in acquired hemophilia with autoantibody inhibitors. In these situations According to the findings of Monroe et al.13 suprapharmacologic doses of rFVIIa can bind non-specifically to the activated platelet without the requirement of TF and subsequently can activate factor X to Xa in the absence of factor VIII or IX. In contrast, the Mann model14 suggests that suprapharmacologic doses of rFVIIa activates coagulation by overcoming an intrinsic inhibition of zymogen FVII in the absence of TF.

Close Modal

or Create an Account

Close Modal
Close Modal